'On consolidated basis

Quarter ended December 2025 compared with Quarter ended December 2024.

Net sales (including other operating income) of Dr Reddys Laboratories has increased 4.44% to Rs 8753.4 crore.  Sales of Pharmaceutical Services segment has gone down 8.81% to Rs 947.20 crore (accounting for 10.62% of total sales).  Sales of Global Generics segment has gone up 7.80% to Rs 7,956.80 crore (accounting for 89.21% of total sales).  Sales of Others segment has gone down 90.64% to Rs 15.10 crore (accounting for 0.17% of total sales).  Inter-segment sales came down from Rs 200.20 crore to Rs 165.70 crore.  

Profit before interest, tax and other unallocable items (PBIT) has slumped 4.57% to Rs 4,681.40 crore.  PBIT of Pharmaceutical Services segment fell 42.35% to Rs 136.00 crore (accounting for 2.91% of total PBIT).  PBIT of Global Generics segment rose 0.42% to Rs 4,541.10 crore (ac...

• 

  (22-Jan-2026)

  Bank of India

  Margins and asset quality improves, strong loan growth
• 

  (22-Jan-2026)

  Oracle Financial Services Software

  Revenue up 14.6% YoY, Net Profit up 12.6% YoY
• 

  (22-Jan-2026)

  Tata Communications

  NP up 54.8% YoY to Rs 365.3 crore in Q3FY2026
• 

  (22-Jan-2026)

  Mastek

  NP up 14.4% YoY to Rs 108.35 crore in Q3FY2026